Dose Escalation in Tigilanol Tiglate Trials: Optimising the Intratumoral Injection

A Dosing Problem Unlike Any Other in Oncology

When investigators design a dose escalation study for a systemic cancer drug — an intravenous infusion, an oral tablet — the variables are relatively well understood. Concentration in plasma rises with dose. Toxicity correlates with plasma exposure. The maximum tolerated dose is the ceiling. For an intratumoral agent like tigilanol tiglate, the situation is fundamentally different.^[1]

The drug never enters systemic circulation at therapeutically meaningful concentrations. Its activity is entirely local. The relevant pharmacokinetic question is not "how much reaches the tumour?" but "how much is too much in the tumour itself?" — and the answer depends not just on dose in milligrams, but on tumour volume, tissue density, injection technique, and the extent of vascular disruption required to achieve complete tumour necrosis.

Translating Veterinary Dosing to Human Trials

The Phase I human trial design for tigilanol tiglate was informed substantially by the extensive preclinical and veterinary data generated by QBiotics Group and QIMR Berghofer. In the Stelfonta approval studies, the dose was expressed as a volume per unit of tumour cross-sectional area — a departure from conventional weight-based or body-surface-area-based dosing that reflects the geometry of intratumoral delivery.^[2][3]

In the canine studies, this area-based dosing approach produced consistent, predictable tumour necrosis across a wide range of tumour sizes and anatomical locations. Translating this approach to human tumours required careful calibration, since human cutaneous and subcutaneous tumours present different tissue architectures, vascular densities, and injection characteristics to canine mast cell tumours.^[2]

The Phase I Design: 3+3 and Beyond

The Phase I tigilanol tiglate study in humans, published by Panizza et al. in 2019, enrolled patients with accessible solid tumours — primarily cutaneous or subcutaneous lesions — that had failed or were unsuitable for standard therapies. The design followed a modified 3+3 dose escalation framework: small cohorts of three patients receiving each dose level, with escalation contingent on acceptable safety in the prior cohort.^[1]

Starting doses were selected based on pharmacological modelling from the veterinary dataset, applying a conservative safety factor. The primary endpoints were dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), with secondary endpoints including objective response rate, duration of response, and pharmacokinetic measurements in tumour tissue and blood.^[1]

Defining Dose-Limiting Toxicity for a Local Agent

Defining DLT for an intratumoral agent required careful thought. Conventional DLT definitions — haematological toxicity, hepatotoxicity, neurotoxicity — were not expected to be primary safety concerns given the localised delivery. Instead, investigators monitored for local adverse events that could indicate over-dosing: excessive tissue damage beyond the tumour margin, prolonged wound healing impairment, or unintended injury to surrounding structures.^[1]

In practice, the Phase I study demonstrated a favourable safety profile across all dose levels tested. Transient local reactions — pain, swelling, and erythema at the injection site — were dose-dependent and expected, representing on-target activity rather than toxicity. Systemic adverse events were rare and mild. No DLT was observed at the doses tested, a finding that contrasts with typical Phase I oncology experience and reflects the localised nature of the compound's mechanism.^[1]

Optimal Biological Dose vs Maximum Tolerated Dose

One of the conceptually important findings from the dose escalation programme was the identification of an optimal biological dose (OBD) — the dose at which consistent, complete tumour necrosis occurred — that was substantially below what would constitute a maximum tolerated dose. In other words, the drug achieved its therapeutic goal at a dose well within the safety margin, with room to spare.^[1][4]

This is a significant distinction. For most cytotoxic agents, clinical development pushes towards the MTD because higher systemic exposure correlates with greater tumour kill. For tigilanol tiglate, the therapeutic goal is achieved by matching dose to tumour volume — ensuring sufficient PKC activation throughout the lesion — rather than by maximising systemic exposure. The dose ceiling is functional, not toxicological.^[3]

What Phase II Has Built On

The dose and volume calculation framework established in Phase I has been carried forward into Phase II studies in head and neck squamous cell carcinoma and soft tissue sarcoma. Phase II has explored not just dose optimisation but injection technique standardisation — critical for intratumoral agents, where operator variability can influence drug distribution within the tumour mass.^[5]

Ongoing work includes combination studies pairing tigilanol tiglate with checkpoint inhibitor immunotherapy, where the necrotic immune priming from tigilanol tiglate may synergise with PD-1 or CTLA-4 blockade to drive systemic anti-tumour responses. In this context, the dose of tigilanol tiglate is being re-examined not as a solo variable but as a determinant of immunogenic signal strength — with implications for how combination schedules are designed.^[5][4]

References

1. 1. Panizza BJ et al. (2019). Phase I Dose-Escalation Study of Intratumoral Tigilanol Tiglate. PubMed. View source ↗
2. 2. FDA Approves Stelfonta — Veterinary Dosing Reference. View source ↗
3. 3. QBiotics Group — Clinical Development Overview. View source ↗
4. 4. QIMR Berghofer — EBC-46 Research Programme. View source ↗
5. 5. ClinicalTrials.gov — Tigilanol Tiglate Trials. View source ↗